Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Comparison of thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant eligible

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Hungria VTM, Crusoe EQ, Maiolino A, Bittencourt R, Fantl D, Maciel JFR, Pessoa de Magalhaes RJ, Almeida MSS, Cury P, Hisgashi F, Peres AL, Chiattone CS (2016) Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible. Ann Hematol 95:271–278

  2. 2.

    National Institute for Health and Care Excellence (2011). Bortezomib and thalidomide for the first-line treatment of multiple myeloma (NICE (Multiple) Technology Appraisal Guidance No. 228). Available at: https://www.nice.org.uk/guidance/TA228 [accessed 16th October 2019]

  3. 3.

    Scottish Medicines Consortium (2009), Medicines advice: thalidomide (SMC 525/08). Available at: https://www.scottishmedicines.org.uk/medicines-advice/thalidomide-pharmion-fullsubmission-52508/ [accessed 16th October 2019]

  4. 4.

    Morgan GJ, Davies FE, Gregory WM (2011) Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 118:1231–1238

Download references

Acknowledgements

The authors are grateful to Christine Crearie and colleagues in the West of Scotland Cancer Network and West of Scotland Haematology Audit Group for support and access to patient data.

Author information

Correspondence to R Soutar.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Soutar, R., Steel, M., Donaldson, A. et al. Comparison of thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant eligible. Ann Hematol (2020). https://doi.org/10.1007/s00277-020-03919-5

Download citation